Pursuant to Article 19 of the Market Abuse Regulation, Matas has received the below notifications from members of management and persons closely …
Check Also
Rebuttal To A Bearish Article About Amarin
Confusion remains about Amarin’s blockbuster trial results for its cardiovascular protection drug, Vascepa. A recent …